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Introduction
Pruritus is the general clinical term for itch, characterized by a generally unpleasant sensation attributed to an area at, or just below, the skin. The sensation is closely related to the reflex desire and action to scratch the afflicted area. Pruritus can greatly reduce the quality of life of those inflicted and is a common symptom attributed to discomfort from dermatological conditions (Stante et al., 2005) .
While there are no collective data on the prevalence of patients seeking treatment for pruritus, the numbers on skin diseases alone estimates an incidence of one in three Americans afflicted at any given moment, costing a yearly $28.3 billion in medical treatment (Bickers et al., 2006) . Due to the great variety of pathophysiological conditions (e.g., anemia, parasites, liver/kidney disease, thyroid disorders, HIV) underlying pruritus symptomology, common treatments are not always effective. Recent studies show pruritus shares much of its neural substrates and signaling characteristics with that of another nocifensive modality, pain. Many of the same receptor systems shown to modulate analgesic actions are also being examined for their effects on itch (e.g. serotonin and opioid), often with antinociception enhancing perception of itch (for review see Paus et al., 2006; Schmelz and Handwerker, 2006 ). Δ 9 -tetrahydrocannabinol (THC), the primary psychoactive component in marijuana, and other cannabinoid receptor agonists produce analgesic effects through the activation of cannabinoid receptors in the periphery, spine, and brain (for review see Pacher et al., 2006) . However, given the occurrence of motor suppression, abuse potential, physical dependence, and psychomimetic effects of THC and other direct-acting cannabinoid agonists, recent efforts in cannabinoid research are focused on examining drugs that prevent the catabolism of endogenous cannabinoids. The endocannabinoid system consists of CB 1 and CB 2 receptors as well as several phospholipid-derived endogenous ligands that bind to these receptors. The most characterized endogenous cannabinoid, anandamide, is rapidly degraded predominantly by the enzyme fatty acid amide hydrolase (FAAH) . Inactivation or inhibition of FAAH greatly increases anandamide levels in brain, spinal cord, liver, and other tissues (Boger et al., 2005; Cravatt et al., 2001; Fegley et al., 2005) . FAAH also degrades several other fatty acid amides with This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on January 23, 2009 as DOI: 10.1124 at ASPET Journals on July 13, 2017 jpet.aspetjournals.org Downloaded from JPET #150136 5 known physiological functions, including oleamide (sleep), N-palmitoyl ethanolamine (PEA; antiinflammatory), and oleoylethanolamide (satiety) (Cravatt et al., 2001) . FAAH (-/-) mice, as well as wild-type mice treated with FAAH inhibitors, possess cannabinoid receptor-mediated hypoalgesic and anti-inflammatory phenotypes, without any signs of significant sedation or muscle relaxation (Lichtman et al., 2004a; Lichtman et al., 2004b) .
Though minimal study has been performed in the area of cannabinoids and pruritus, cannabinoid receptor agonists tend to decrease scratching behavior, while cannabinoid receptor antagonists, such as rimonabant, elicit a dose-dependent increase in scratching behavior in mice (Darmani and Pandya, 2000) . Interestingly, several mixed CB 1 /CB 2 receptor agonists (i.e., THC, WIN55212-2, CP55940, and HU-210) potently reversed rimonabant-induced scratching in an order similar to their potency to elicit known cannabinoid mediated behavioral effects (Janoyan et al., 2002) . Additionally, each of these cannabinoids also reduced scratching elicited by the 5-HT 2A/C receptor agonist, DOI (Darmani, 2001 ).
In limited case reports, dronabinol (oral THC) relieved intractable pruritus resulting from liver cholestasis (Neff et al., 2002) , a common clinical cause of severe and prolonged pruritus. Finally, transdermal application of the potent cannabinoid receptor agonist, HU-210, significantly reduced the perception of itch elicited by histamine iontophoresis in a small group of healthy volunteers (Dvorak et al., 2003) . Taken together, the above evidence suggests that cannabinoids may provide a novel therapeutic target for both peripheral and central inhibition of pruritus. Presently, there are no published studies of which we are aware that have examined the role of FAAH in an animal model of pruritus.
The overall objective of the present study was to elucidate the therapeutic potential of targeting the endocannabinoid system to treat pruritus. A model using the mast cell degranulator, compound 48/80, that directly activates signaling events characteristic of an acute allergenic response was adapted from Sugimoto et al. (1998) 
Methods
Subjects
Tests utilizing transgenic animals (i.e. FAAH, CB 1 , and CB 2 knockout animals) and their controls were performed on mice from the Center Transgenic Colony at Virginia Commonwealth University (Richmond, VA) backcrossed onto either a C57BL/6J (13 generations) or DBA/1 (6 generations) background. All other experiments utilized adult male C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME), except one intravenous study employing male ICR mice (Harlan Laboratories, Indianapolis, IN). Mice were housed 4-6 per cage in a temperature (20-22°C) controlled environment, with food and water available ad libitum while in their home cages. Mice were kept on a 12-hour light/dark cycle, with all experiments performed during the animals' light period. All experiments were performed with the approval of the Institutional Animal Care and Use Committee at Virginia Commonwealth University in accordance with the Guide for the Care and Use of Laboratory Animals.
Drugs
THC and rimonabant were obtained from the National Institute on Drug Abuse (Bethesda, MD) and OL-135 was synthesized as previously described (Boger et al., 2005) . URB597 was purchased from Cayman Chemical (Ann Arbor, MI), while compound 48/80, diphenhydramine, dexamethasone, and loratadine were purchased from Sigma (St. Louis, MO). Compound 48/80, diphenhydramine, dexamethasone, and loratadine were dissolved in 0.9% saline, while all other drugs were dissolved in vehicle mixture of ethanol/alkamuls-620 (Rhone-Poulenc, Princeton, NJ)/saline in a ratio of 1:1:18.
Drugs were diluted to an injection volume of 10 µl/g body mass and injected via intraperitoneal diphenhydramine, the non-sedating antihistamine loratadine, and the glucocorticoid dexamethasone, were each administered 30 min prior to compound 48/80 injection. The reversible FAAH inhibitor OL-135 and the irreversible FAAH inhibitor URB597 were both administered 1 h before compound 48/80, based on previous reports showing anandamide levels peaked at that time (Fegley et al., 2005; Lichtman et al., 2004a) . In one study, URB597 was administered intravenously 10 min after application of compound 48/80 to examine reversal of scratching. In all studies utilizing rimonabant, the selective CB 1 receptor antagonist was administered 15 min prior to compound 48/80.
Behavioral Evaluation of Scratching Response
Animals were pretreated with test drugs at times described for individual experiments. All animals were placed into white (for contrast) acrylic chambers (20 cm x 20 cm x 20 cm), with a clear acrylic front panel and a mirrored back panel, for 30 min to acclimate to the observational environment. The chambers were enclosed in sound-attenuating cabinets, designed and custom built at Virginia Commonwealth University, that contained an indirect filtered LED light source and fans for air circulation and white noise. At the 30 min time point, animals were briefly removed from the chambers, which were wiped clean with water. Subjects were then given an injection of compound 48/80 under the scruff at the most dorsal point of the back just beneath the head, and were returned to the chambers for a 30 min. Behavior was recorded through the clear front panel using a series of Fire-i™ digital cameras (Unibrain, San Ramon, CA) and the videos were processed and saved using ANY-maze™ video tracking software (Stoelting Co., Wood Dale, IL). Chambers were fully sanitized at the end of each testing day using ammonia-based cleansers and soap, then left to air dry at least two days to dissipate any odors.
The videos were subsequently placed in randomized order in a separate ANY-maze™ protocol for a trained observer to score using a keyboard-based behavioral tracking system, blinded to treatment group.
Either ANY-maze™ or ODLog™2 (Macropod Software, Armidale, NSW, Australia) software was used to track key presses assigned to specific behavioral endpoints for both time pressed and number of occurrences. The scratching response was tracked as hind leg scratching of the injection site and surrounding areas, excluding behaviors focused at areas within the ears or flicking and pulling at ear tags. Behavioral locomotor inactivity was also monitored, scored as complete lack of voluntary movement for any continuous period longer than 5 s.
Data Analysis
All data are reported as mean ± SEM, and represent the total number of seconds a specific behavior was scored from a total observational period of 1800 sec. Experiments with only two treatment groups were analyzed for statistical significance using Student's t test. Experiments with more than two groups were analyzed using one-or two-way analysis of variance (ANOVA), with specified appropriate posthoc test. Resulting p values of less than 0.05 were considered significant. ED 50 values (with 95% confidence intervals), as well as the potency ratios derived from the ED50 values, were calculated using the least-squares linear regression method. Significant differences in potency were determined by the 95% confidence intervals of the potency ratio not including a ratio of 1.
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Results
Pruritic Response to Compound 48/80
In an initial experiment, we evaluated the compound 48/80 model as a reliable model of pruritus by examining a similar dose range as used by Sugimoto et al. (1998) To validate further the allergenic pruritus model, a pair of drugs representing the most common classes of clinically effective treatments for allergenic itch was tested against compound 48/80 (30 µg).
The glucocorticoid compound, dexamethasone (2 mg/kg i.p.) significantly reduced scratching compared to saline pretreatment [t(14) = 6.1, p < 0.001]. In an initial study, we attempted to examine the doseresponse relationship of diphenhydramine, an over-the-counter and commonly used H 1 receptor antagonist. However, a significant reduction in scratching only occurred at doses that also elicited profound hypothermia and almost complete immobility (data not shown). The non-sedating second generation H 1 receptor antagonist, loratadine (10 mg/kg i.p.), significantly reduced scratching behavior compared to vehicle controls [t(10) = 4.8, p < 0.001]. No significant effects of behavioral locomotor inactivity were found for either dexamethasone or loratadine. The results of these tests are summarized in Table 1 .
Evaluation of THC Treatment
Intraperitoneal administration of THC dose-dependently attenuated compound 48/80-induced scratching [F(4,35) = 15.3, p < 0.001; Figure 2A ]. The resulting curve shows that THC possessed great As THC binds to both CB 1 and CB 2 receptors, we evaluated its receptor mechanism of action using mice lacking functional CB 1 or CB 2 receptors. As shown in Figure 3A , THC (1 mg/kg) significantly reduced scratching behavior in the CB 1 (+/+) mice, but did not cause any significant changes in the CB 1 (-/-) mice [F(1,28) = 8.9, p < 0.01 for interaction between genotype and THC pretreatment]. Compound 48/80 produced significantly less scratching behavior in CB 1 (-/-) mice than in CB 1 (+/+) mice (p < 0.01, Tukey's post-hoc). In addition, there was a significant interaction between genotype and THC on the locomotor activity data [F(1,28) = 15.5, p < 0.001]. THC more than doubled the time that the CB 1 (+/+) mice spent inactive (vehicle: 208 ± 62 sec, THC: 532 ± 46 sec), but did not significantly affect the CB 1 (-/-) mice. However, CB 1 (-/-) mice were significantly less active than the CB 1 (+/+) mice under vehicle conditions (p < 0.01, Tukey's post-hoc). In contrast, CB 2 (-/-) mice exhibited similar scratching responses and levels of inactivity compared to CB 2 (+/+) mice under vehicle treatment (see Figure 3B ).
In addition, both genotypes showed equivalent responses to treatment with THC with respect to both scratching suppression and behavioral inactivity, with only a resulting main effect of THC treatment for 
Evaluation of FAAH (-/-) Mice Scratching Response
FAAH (-/-) mice display impaired catabolic activity to anandamide and other fatty acid amides, resulting in at least 10-fold increases in endogenous levels of these lipid signaling molecules (Cravatt et al., 2001 ). The effects of compound 48/80 challenge in FAAH (-/-) mice backcrossed onto either C57BL/6 (C57) or DBA/1 (DBA) genetic backgrounds are shown in Figure 4 . FAAH (-/-) mice demonstrated a significantly reduced scratching response to compound 48/80 compared to FAAH (+/+) mice in both C57 [t(14) = 2.5, p < 0.05] and DBA [t(14) = 2.3, p < 0.05] strains. Neither the C57 nor DBA strains of FAAH (-/-) mice showed any differences in time spent inactive during testing (Table 2 ).
These two background strains were examined because C57 mice were used in most other behavioral tests presented here, and the neural specific FAAH knock-in (i.e., FAAH-NS) mice available for this research was developed on the DBA background.
While numerous biologically activated fatty acid amides are elevated in mice lacking functional FAAH activity, anandamide is the only mediator that has shown high affinity for activating cannabinoid receptors. To test whether anandamide and CB 1 receptors contribute to the FAAH (-/-) phenotypic reduction in scratching, a moderate dose of rimonabant (1 mg/kg, i.p.) was given 15 min prior to compound 48/80. As seen in Figure 5 , the vehicle-treated FAAH (-/-) mice displayed a significant reduction in scratching behavior compared to the vehicle-treated FAAH (+/+) mice. The dose of rimonabant did not affect scratching in FAAH (+/+) mice, but significantly reversed the FAAH (-/-) phenotype [F(1, 28) = 20.0, p < 0.001 for interaction between rimonabant and genotype], indicating a CB 1 receptor mechanism. There were no significant effects of either FAAH genotype or rimonabant pretreatment on locomotor activity (Table 2) .
Because CB 1 receptors are expressed in both the CNS and periphery, we next evaluated the contribution of FAAH activity in neural tissues. FAAH-NS mice are conditional knock-in mice with FAAH expression linked to the promoter for neural-specific enolase, resulting in mice that express FAAH exclusively in neuronal tissue (i.e., brain, spinal cord, and dorsal root ganglia). Thus, these mice cord, but have greatly elevated levels of these lipid signaling molecules in peripheral organs . A comparison of FAAH-NS mice to FAAH (-/-) and FAAH (+/-) controls (on a DBA/1 background strain) is shown in Figure 6 . FAAH (+/-) mice exhibited a similar response to compound 48/80 as wild-type animals, while FAAH (-/-) mice continued to display a significant reduction in scratching [F(2, 26) = 9.7, p < 0.001; Figure 6A ]. The observation that the FAAH-NS mice showed a similar magnitude of scratching to compound 48/80 as wild-type mice indicates that neuronal fatty acid amides regulate this response. Despite scratching significantly more than FAAH (-/-) mice, and the same as FAAH (+/-) mice, FAAH-NS showed a significant increase in time spent inactive (Table 2) .
This pattern of findings shows that scratching and hypomotility can be functionally uncoupled.
Treatment of Scratching by FAAH Inhibitors
In the final series of experiments, we evaluated the effects of the selective FAAH inhibitors, URB597 and OL-135, in the compound 48/80 pruritus model. As seen in Figure 7 , and summarized in Table 1 Because pruritic conditions are treated after persistent itching and are not treated prophylactically, we next investigated whether URB597 would reverse scratching after the allergenic response was already initiated. Accordingly, ICR mice were given compound 48/80 and monitored before and after either vehicle or URB597 (1 mg/kg) intravenous treatment. As shown in Table 3 , both groups showed equivalent levels of scratching response over the initial 10 min after compound 48/80 (i.e., before drug treatment). At the conclusion of the first 10 min time block, the mice were removed from the observation cage, immediately given an injection of either vehicle or URB597 (10 mg/kg) into the tail vein, and returned to the test chamber by 11 min. Mice were then scored again for the final 10 min of the compound 48/80 scratching (i.e., from 20 to 30 min after compound 48/80 administration), allowing 10 min without scoring for onset of drug action. After the i.v. injection, both groups showed less scratching behavior than during the first 10 min time block, in line with a typical compound 48/80 timecourse. Importantly, URB597 injected after the induction of compound 48/80-induced scratching significantly attenuated scratching behavior compared to vehicle-treated mice. Additionally, the vehicle-and URB597-treated groups displayed a similar degree of hypomotility at each respective time block.
To examine the receptor mechanism of action, we evaluated the effects of URB597 on compound 48/80-induced scratching in CB 1 (-/-) and CB 2 (-/-) mice (see Figure 8 ). URB597 significantly decreased scratching in CB 1 (+/+) mice, but was without effect in CB 1 (-/-) mice [F(1,30) = 5.9, p < 0.05 for interaction between URB597 and genotype; Figure 8A ]. There was also a significant increase in behavioral locomotor inactivity, regardless of treatment, in the CB 1 (-/-) mice [F(1,30) = 15.0, p < 0.001 for genotype; Table 2 ]. Because vehicle-treated CB 1 (-/-) mice displayed a reduced scratching response compared to vehicle-treated CB 1 (+/+) mice (p = 0.05, Tukey's post hoc), we next evaluated whether rimonabant would block the reduction of scratching behavior caused by URB597. As depicted in Figure   This Table 2 ). In contrast, URB597 elicited a similar attenuation of scratching in both CB 2 (+/+) and (-/-) mice [F(1,20) = 23.9, p < 0.001 for main effect of URB597; Figure 8C ]. In addition, both CB 2 (+/+) and (-/-) mice displayed a similar degree of scratching behavior as well as activity levels (Table 2 ). These data indicate that CB 1 receptors are critical for URB597's attenuation of compound 48/80-induced scratching.
Finally, to validate the specificity of both the transgenic and pharmacological tools, the effects of vehicle or URB597 (10 mg/kg) were evaluated in FAAH (+/-), FAAH (-/-), and FAAH-NS mice to ascertain the locus of action. In a replication of the previous experiment shown in 
Discussion
Pruritus represents a significant clinical problem that can produce great suffering in affected patients that includes 70% of patients suffering from liver cholestasis, as well as approximately 20% in kidney failure and most patients with atopic dermatitis. In fact, upwards of 50% of all pruritus cases requiring medical treatment may result from a systemic, chronic underlying pathology (Bernhard, 1994) . None of the aforementioned conditions have pharmacotherapies available that consistently alleviate the pruritus.
The research presented in the present manuscript is the first to examine the therapeutic and mechanistic roles of the endogenous cannabinoid system in the modulation of pruritus. Here, we demonstrate that THC, as well as pharmacological blockade or genetic deletion of FAAH, reduces scratching in a murine model of pruritus.
FAAH (-/-) mice, as well as mice treated with FAAH inhibitors, displayed a significant decrease in compound 48/80-induced scratching with the absence of motor suppression. The converging evidence from FAAH (-/-) mice and two separate classes of FAAH inhibitors suggests that inactivation of this enzyme, resulting in elevated levels of several fatty acid amides, leads to inhibition of pruritic responses.
The ED 50 values of URB597 and OL-135 in attenuation of scratching response closely matched those previously reported for inhibition of FAAH and/or enhancement of activity from exogenously administered anandamide (Lichtman et al., 2004a; Piomelli et al., 2006) . The FAAH inhibitors URB597 and OL-135 show similar efficacy in scratching suppression as current treatments of choice for allergenic pruritus (Table 1) leads to increased endogenous anandamide levels, it also increases content of other fatty acid amides important to cellular signaling (Cravatt et al., 2001) . Of note, topical creams containing a noncannabinoid substrate of FAAH, PEA, suppressed ratings of pruritus in a small clinical study of volunteers with various chronic dermatological conditions (Stander et al., 2006) . Although no mechanistic studies were performed, most evidence points to PEA providing anti-inflammatory action through PPARα nuclear receptors (Lo Verme et al., 2005) . The FAAH (-/-) phenotypic reduction in scratching was completely reversed by 1 mg/kg of the CB 1 antagonist, rimonabant. Similarly, the FAAH inhibitor, URB597, failed to attenuate scratching behavior in CB 1 (-/-) mice or rimonabanttreated wild type mice. Conversely, URB597 continued to elicit full antipruritic effects in CB 2 (-/-) mice. Moreover, these findings are consistent with the notion that elevated levels of anandamide mediate this phenotype because it is the only known substrate of FAAH that binds to CB 1 receptors.
Through the use of FAAH-NS mice, we evaluated whether FAAH activity in the nervous system plays an important role in modulating scratching behavior in the compound 48/80 model. Interestingly, FAAH-NS mice that express wild type levels of fatty acid amides in the nervous system, but elevated levels in peripheral organs ) exhibited a similar scratching response as wild-type mice. Thus, despite possessing elevated levels of fatty acid amides in the peripheral organs, these mice have no phenotypic attenuation of pruritus. Furthermore, administration of URB597 to FAAH-NS mice, which inhibited the remaining active FAAH in the nervous tissues, suppressed the scratching response in a fashion similar to wild-type controls. These suppressed scratching responses mimicked that of FAAH knockout mice in magnitude, and no further reductions of URB597 were seen in global FAAH knockout mice. The above results show the apparent specificity of the scratching phenotype of both the drug and transgenic models to their FAAH activity, and indicate that FAAH inhibition within the nervous system is essential for antipruritic action. These findings suggest that this enzyme may be targeted for therapeutic gain to treat a generalized pruritus from a wide variety of etiologies, including immunological, neuropathic, and psychogenic. This study also demonstrated that even though systemic THC is capable of near full suppression of pruritic scratching response to compound 48/80, its effects are accompanied with overt CNS behavioral effects. Subcutaneous THC administered locally to the site of compound 48/80 potently suppressed scratching response, supporting previous evidence that locally applied cannabinoid agonists have antipruritic action (Dvorak et al., 2003) , though suppression was observed in a narrow dose range before also eliciting central inhibitory effects. The profile of THC in the compound 48/80 model is similar to animals pretreated with systemic diphenhydramine, a well-established antihistamine that has sedative and adverse CNS effects, limiting its use when patient sedation and cognition are considerations (for review see Banerji et al., 2007) . Pretreatment with dexamethasone and loratadine, representing commonly used non-sedative treatments of allergenic pruritus, produced effective suppression of scratching response to compound 48/80 with minimal effects on locomotor activity and sedation. The suppression of scratching observed following THC administration was absent in CB 1 knockout mice, but equally effective in CB 2 knockout mice, suggesting that at least most of THC's antipruritic actions are attributable to activation of CB 1 receptors. However, the observation that THC also increased hypomotility suggests that at least a portion of the suppression seen may be attributed to central sideeffects at higher doses.
Therapeutic use of THC is hindered by many issues associated with chronic use. THC has been shown to have potential for abuse, as THC has been shown to be self-administered in primates (Justinova et al., 2008) , and shows a withdrawal syndrome indicative of physical dependence in humans (Haney et al., 1999) . In contrast, the FAAH inhibitor URB597 appear to lack abuse potential, with no conditioned place preference in rodents (Gobbi et al., 2005) , and no self-administration in primates (Justinova et al., 2008) . In addition, URB597 does not appear to elicit cannabimimetic subjective effects, as it fails to substitute for THC in drug discrimination tests in rodents (Solinas et al., 2007) . Previous studies show pruritus may be gated by inhibitory input from nociceptive pathways.
Noxious cooling and heating, along with scratching itself, produce increases in pain ratings with associated decreases in itch (Ward et al., 1996; Yosipovitch et al., 2005; Yosipovitch et al., 2007) .
Compared to either histamine or noxious cold alone, human subjects had selective neural activation of the periaqueductal gray (PAG) during induction of both pruritus and pain together (Mochizuki et al., 2003) . The PAG having such a pronounced role in the inhibition of nociception suggests that this brain region may also inhibit pruritus (Waters and Lumb, 2007) . Considering that opioid (Rosenfeld, 1994) and cannabinoid (Lichtman et al., 1996) (Bigliardi et al., 2007; Mansour-Ghanaei et al., 2006; Wikstrom et al., 2005) . Unlike the 
